TickerHumNASDAQ · Healthcare · Drug Manufacturers—General
Biogen Inc. (BIIB)
As of Nov 11, 4:00 PM ET, Biogen (BIIB) last traded at $253.40, up 0.06% on the day. Its TickerHum research score is 53/100 (average). It reported revenue of $10.3B for the twelve months ending 2026-09-30, up 2.3% year over year.
Ratings
- Valuation: 54/100 — Strongest input: price / sales (ttm) 3.6x. Weakest: price / earnings (ttm) 109.7x.
- Growth: 16/100 — Strongest input: revenue growth (ttm, yoy) +2.3 %. Weakest: diluted eps growth (ttm, yoy) -78.9 %.
- Profitability: 27/100 — Strongest input: net margin 3.4 %. Weakest: return on equity 1.8 %.
- Financial health: 53/100 — Strongest input: long-term debt / equity 0.39. Weakest: cash / long-term debt 0.18.
- Momentum: 91/100 — Strongest input: price vs 200-day average +24.0 %. Weakest: 6-month return +23.9 %.
- Attention: 58/100 — Strongest input: headlines in the last 7 days 14. Weakest: volume vs 3-month average 1.0x.
- Risk resilience: 77/100 — Strongest input: max drawdown (1y) -14.3 %. Weakest: annualised volatility (1y) 34.3 %.
- Data confidence: 97/100 — Strongest input: quote age (hours) 8 h. Weakest: inputs available 90 %.
Reported fundamentals
| Metric | Value | Period |
|---|---|---|
| Revenue | $10.3B | TTM ending 2026-09-30 · 10-Q |
| Revenue growth | 2.3% | TTM ending 2026-09-30 · 10-Q |
| Net income | $347.5M | TTM ending 2026-09-30 · 10-Q |
| Diluted EPS | $2.31 | TTM ending 2026-09-30 · 10-Q |
| Net margin | 3.4% | TTM ending 2026-09-30 · 10-Q |
| Free cash flow | $2.07B | TTM ending 2026-09-30 · 10-Q |
| Cash | $1.3B | as of 2026-09-30 · 10-Q |
| Long-term debt | $7.29B | as of 2026-09-30 · 10-Q |
| Debt / equity | 0.39 | as of 2026-09-30 · 10-Q |
Source: SEC EDGAR XBRL company facts (CIK 0000875045).
Comparable companies for Biogen
Selected by industry, business overlap and scale; these are not necessarily direct competitors.
- Biogen vs Bristol-Myers Squibb (BIIB vs BMY) — Same industry (Drug Manufacturers—General); market cap 3.4x
- Biogen vs Pfizer (BIIB vs PFE) — Same industry (Drug Manufacturers—General); market cap 4.5x
- Biogen vs Gilead Sciences (BIIB vs GILD) — Same industry (Drug Manufacturers—General); market cap 5.6x
- Biogen vs Amgen (BIIB vs AMGN) — Same industry (Drug Manufacturers—General); market cap 6.8x
- Biogen vs Merck & Co. (BIIB vs MRK) — Same industry (Drug Manufacturers—General); market cap 9.7x
Prices: Yahoo Finance (public) — Free public Yahoo Finance data. Prices may be delayed and are for information only.